| タイトル |
Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX
|
| 著者 |
Harvey N. C.
Kanis J. A.
Oden A.
Nakamura T.
Shiraki M.
Kuroda T.
Johansson H.
McCloskey E. V.
|
| 収録物名 |
OSTEOPOROSIS INTERNATIONAL
|
| 巻 | 26 |
| 号 | 9 |
| 開始ページ | 2347 |
| 終了ページ | 2353 |
| 収録物識別子 |
ISSN 0937-941X
EISSN 1433-2965
|
| 主題 | |
| 言語 |
英語
|
| 資源タイプ | 学術雑誌論文 |
| 出版者 |
SPRINGER LONDON LTD
|
| 発行日 | 2015-09 |
| アクセス権 | メタデータのみ |
| 関連情報 |
[DOI] 10.1007/s00198-015-3129-7
[PMID] 26092062
|
| 備考 | NH has received consultancy, lecture fees, and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, Consilient Healthcare, and Internis Pharma. JA Kanis has received consulting fees, advisory board fees, lecture fees, and/or grant support from the majority of companies concerned with skeletal metabolism. EVM has received consultancy, lecture fees, research grant support, and/or honoraria from ActiveSignal, Alliance for Better Bone Health, AMGEN, Bayer, Consilient Healthcare, GE Lunar, Hologic, Internis Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Servier, Tethys, UCB, and Univadis. TN received research grants and/or consulting fees from Chugai Pharmaceutical, Teijin Pharma, Asahi Kasei Pharma, and Daiichi Sankyo. MS received consulting fees from Chugai, Daiichi Sankyo, Asahi Kasei Pharma, Teijin Pharma, and MSD. TS received consulting fee and/or research grant from Asahi-Kasei Pharma, Daiichi-Sankyo-Co., Eli Lilly Japan, and Pfizer. TK is an employee of Asahi Kasei Pharma Corporation. Anders Oden and Helena Johansson declare that they have no conflict of interest. |
